The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma.

Zhang, Lishuo; Di, Longjiang; Liu, Jinhui; Lei, Xianli; Gu, Maoli; Zhang, Wenjing; Wang, Yufu

Zhang, Lishuo; Di, Longjiang; Liu, Jinhui; Lei, Xianli; Gu, Maoli; Zhang, Wenjing; Wang, Yufu.

Afiliación

Zhang L; Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Di L; College of Basic Medicine, Southern Medical University, Guangzhou, Guangdong, China.
Liu J; The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Lei X; Harbin Medical University, Harbin, Heilongjiang, China.
Gu M; Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Zhang W; The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Wang Y; The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.

Front Genet ; 14: 1039813, 2023.

Article en En | MEDLINE | ID: mdl-36755568

Palabras clave

clear cell renal cell carcinoma; cuproptosis; immunotherapy; long non-coding RNA; prognosis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Idioma: En Revista: Front Genet Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google